[
  {
    "ts": "2026-02-20T07:00:00+00:00",
    "headline": "U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA速 (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)",
    "summary": "AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the combination regimen of VENCLEXTA速 (venetoclax) and acalabrutinib for the treatment of previously untreated adult patients with chronic lymphocytic leukemia (CLL). The approval is supported by data from the Phase 3 AMPLIFY trial.1",
    "url": "https://finance.yahoo.com/news/u-food-drug-administration-fda-070000361.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "dbec8ad6-6a0a-3b71-98b4-e19c0df9e3cc",
      "content": {
        "id": "dbec8ad6-6a0a-3b71-98b4-e19c0df9e3cc",
        "contentType": "STORY",
        "title": "U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA速 (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)",
        "description": "",
        "summary": "AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the combination regimen of VENCLEXTA速 (venetoclax) and acalabrutinib for the treatment of previously untreated adult patients with chronic lymphocytic leukemia (CLL). The approval is supported by data from the Phase 3 AMPLIFY trial.1",
        "pubDate": "2026-02-20T07:00:00Z",
        "displayTime": "2026-02-20T07:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/41f69f15bd3bc61c4f58a58b4cb0aef6",
          "originalWidth": 16,
          "originalHeight": 16,
          "caption": "Cision",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_lYBdZ6deIjyT9JEkTbBlQ--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/41f69f15bd3bc61c4f58a58b4cb0aef6.cf.webp",
              "width": 16,
              "height": 16,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lbpa0nBqHlbEGEv5DWOrMQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/41f69f15bd3bc61c4f58a58b4cb0aef6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/u-food-drug-administration-fda-070000361.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/u-food-drug-administration-fda-070000361.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]